21st Austria weekly - Marinomed Amag Uniqa 16/02/2023 [pic1]Marinomed: Marinomed Biotech AG listed on the Vienna Stock Exchange achieved a further increase in demand for Carragelose products 2022. According to preliminary figures revenues were up by 15.5% € 11.2 m 2021: 9.7 m. This positive development resulted stable of 11.3 full year 11.6 m despite lack milestone payments Adjusted Budesolv payment 1.9 2021 have increased 16.5 %. Cash and cash equivalents 8.2 5.8 m; +41% reflecting low burn-rate throughout 2022 due profitable inflows from loans real estate financings convertible bond program with Nice & Green.Marinomed Biotech: